TRELEGY ELLIPTA 100-62.5-25

What it is

TRELEGY ELLIPTA 100-62.5-25 is how the CMS NADAC file names this product. The FDA NDC Directory lists it as fluticasone furoate, umeclidinium bromide and vilanterol trifenatate, under the trade name “Trelegy Ellipta”.

FDA gives its dosage form as powder and its route as respiratory (inhalation).

The labeler, the company named on the label, is GlaxoSmithKline LLC.

FDA lists it under 3 Established Pharmacologic Classes: Anticholinergic, beta2-Adrenergic Agonist and Corticosteroid.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $11.08 – $11.15 for 1 unit (EA), depending on the NDC ($11.07954 to $11.15225 per EA), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

What NADAC measures · NADAC explanation codes

All 2 NDCs

• 00173-0887-10 · GlaxoSmithKline LLC · $11.15225 per EA · eff. 2026-09-23 filed
• 00173-0887-14 · GlaxoSmithKline LLC · $11.07954 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name fluticasone furoate, umeclidinium bromide and vilanterol trifenatate with TRELEGY ELLIPTA 100-62.5-25.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $11.07954 per EA filed.

Of the 23 other products in FDA’s Anticholinergic class priced per EA, 3 have a higher middle NADAC price and 20 a lower one. The one in the middle is LOMOTIL 2.5-0.025 MG TABLET, at $2.99096 per EA filed (eff. 2026-09-23).

Of the 26 other products in FDA’s beta2-Adrenergic Agonist class priced per EA, 5 have a higher middle NADAC price and 21 a lower one. The one in the middle is FLUTICASONE-VILANTEROL 200-25, at $3.91371 per EA filed (eff. 2026-09-23).

Of the 73 other products in FDA’s Corticosteroid class priced per EA, 16 have a higher middle NADAC price and 57 a lower one. The one in the middle is FLUTICASONE PROP 100 MCG DISKUS, at $2.05252 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $10.52 for 1 unit (EA), at an average of $10.51883 per EA in 2024 (2024-01-01 to 2024-12-31) for “Trelegy Ellipta” and “Fluticasone/Umeclidin/Vilanter”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 6,250,872 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 1 unit (EA)? Is it lower than what I would pay through my insurance?
• Which NDC (the 11-digit number on the package) is this? Pharmacies pay $11.07954 to $11.15225 per EA for this product, depending on the NDC.
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.